Int Arch Allergy Immunol:过敏性鼻炎和哮喘的尘螨属螨虫敏感的分布的决定因素分析

2019-05-24 AlexYang MedSci原创

过敏原免疫治疗(AIT)需要知道过敏原的分布信息,从而来鉴定AIT使用的高风险区域。然而,虽然尘螨属过敏原的流行率越来越高,这些过敏原在中国的地理分布模式仍旧不清楚。研究人员回顾了163篇文章,这些文章包括了阳性过敏原的案例,研究人员利用这些信息产生了过敏原分布图。研究人员发现,屋尘螨和粉尘螨敏感的比例在过敏性鼻炎(AR)患者中的分布相似(75.1 vs. 75.2%, p>0.05),但是

过敏原免疫治疗(AIT)需要知道过敏原的分布信息,从而来鉴定AIT使用的高风险区域。然而,虽然尘螨属过敏原的流行率越来越高,这些过敏原在中国的地理分布模式仍旧不清楚。

研究人员回顾了163篇文章,这些文章包括了阳性过敏原的案例,研究人员利用这些信息产生了过敏原分布图。研究人员发现,屋尘螨和粉尘螨敏感的比例在过敏性鼻炎(AR)患者中的分布相似(75.1 vs. 75.2%, p>0.05),但是在过敏性哮喘(AA)中不相似(78.5 vs. 77.7%, p=0.041)。患有AR和AA的患者具有相似的屋尘螨和粉尘螨敏感地区分布模式,其中在中国的南方和中原最高,在中国北部最低,尤其是西北地区。对屋尘螨和粉尘螨敏感的总比例在AA患者中显著更高(p<0.001)。另外,年平均温度和湿度是AR屋尘螨和粉尘螨敏感的和哮喘屋尘螨敏感的2个主要决定因素,而年平均温度是哮喘粉尘螨过敏的唯一决定因素。

最后,研究人员指出,他们的发现为医生对尘螨属敏感的预防提供了策略,并且也许对未来尘螨敏感患者的治疗有益。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671035, encodeId=842816e1035f1, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Jan 24 05:28:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704046, encodeId=c5bb1e04046d3, content=<a href='/topic/show?id=ce13888e8db' target=_blank style='color:#2F92EE;'>#螨虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88878, encryptionId=ce13888e8db, topicName=螨虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5a630645797, createdName=宋威, createdTime=Thu Feb 20 17:28:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047121, encodeId=32e0204e121bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 27 02:28:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329245, encodeId=640e132924558, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun May 26 04:28:00 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671035, encodeId=842816e1035f1, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Jan 24 05:28:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704046, encodeId=c5bb1e04046d3, content=<a href='/topic/show?id=ce13888e8db' target=_blank style='color:#2F92EE;'>#螨虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88878, encryptionId=ce13888e8db, topicName=螨虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5a630645797, createdName=宋威, createdTime=Thu Feb 20 17:28:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047121, encodeId=32e0204e121bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 27 02:28:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329245, encodeId=640e132924558, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun May 26 04:28:00 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
    2020-02-20 宋威
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671035, encodeId=842816e1035f1, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Jan 24 05:28:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704046, encodeId=c5bb1e04046d3, content=<a href='/topic/show?id=ce13888e8db' target=_blank style='color:#2F92EE;'>#螨虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88878, encryptionId=ce13888e8db, topicName=螨虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5a630645797, createdName=宋威, createdTime=Thu Feb 20 17:28:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047121, encodeId=32e0204e121bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 27 02:28:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329245, encodeId=640e132924558, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun May 26 04:28:00 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671035, encodeId=842816e1035f1, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Jan 24 05:28:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704046, encodeId=c5bb1e04046d3, content=<a href='/topic/show?id=ce13888e8db' target=_blank style='color:#2F92EE;'>#螨虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88878, encryptionId=ce13888e8db, topicName=螨虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5a630645797, createdName=宋威, createdTime=Thu Feb 20 17:28:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047121, encodeId=32e0204e121bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 27 02:28:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329245, encodeId=640e132924558, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun May 26 04:28:00 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
    2019-05-26 膀胱癌

相关资讯

Am J Rhinol Allergy:非过敏性鼻炎患者的临床特性区分

并不是所有的鼻炎患者均受免疫球蛋白E(lgE)调控的炎症过程影响。由于皮刺和血清过敏原评估受限,因而不能对局部过敏性鼻炎(LAR)进行确诊。因此,具有阴性系统性过敏评估的患者其实包括了非过敏性鼻炎患者(NAR)和LAR患者。最近,有研究人员确定了NAR患者的临床特性。研究是一个代表性的研究,包括了154名参与者(平均年龄为41.79±14.78岁,37.7%的为女性 )。与AR患者相比,NAR患者

Environ Int:家庭清洗剂的使用和呼吸道与过敏症状研究

有研究指出,家庭中使用清洗剂的成年人的哮喘和过敏性症状风险更高。在青少年中,哮喘和过敏性症状与清洗剂之间的相关性还没有调查。最近,有研究人员在青少年中调查了家庭清洗剂的使用与哮喘、鼻炎和湿疹患病率之间的关系。研究是一个代表性的研究,数据包括了10种清洗剂和有关哮喘、鼻炎和湿疹的信息(n=2333,年龄14)。研究发现,年龄为14岁的参与者中,哮喘、鼻炎和湿疹的患病率分别为7%、13%和11%。家庭

盘点:鼻炎研究小结

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Clin Exp Otorhinolaryngol:长期母乳喂养在预防过敏性鼻炎中的作用分析 https://www.ncbi.nlm.nih.gov/pubmed/309

盘点:鼻炎治疗研究小结

【1】Clin Exp Otorhinolaryngol:虎耳草在过敏性鼻炎中的抗过敏作用研究 https://www.ncbi.nlm.nih.gov/pubmed/30942049虎耳草提取物具有抗癌、抗过敏和抗氧化活性。最近,有研究人员调查了虎耳草提取物对过敏性鼻炎炎症中的作用。研究包括了4个不同的小组(组A:对照组;组B:过敏性鼻炎组;组C:300mg/kg处理组;组D:600mg/k

Allergy Asthma Proc:奥洛他定-莫米松组合鼻喷剂在季节过敏性鼻炎患者中的效果和安全性评估

GSP301是一种研究用的固定剂量组合鼻喷剂,其中包含了抗组胺剂、盐酸洛普他定(HCI)和皮质类固醇糠酸莫米他松。最近,有研究人员评估了GSP301在季节过敏性鼻炎(SAR)患者中的效果和安全性。研究是一个双盲、随机和平行的研究。研究总共包括了1180名患者。在经过14天的治疗后,与安慰剂组(最小平方平均差-0.98;95%CI,-1.38到-0.57;p<0.001)和奥洛他定治疗组(p=

EBioMedicine:IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关

自身免疫和过敏与调节T细胞(Tregs)数目的减少和低水平的白介素-2(IL-2)相关。最近,有研究人员调查了在童年早期,是否病原气道细菌刺激外周血单核细胞(PBMCs)而释放的IL-2与过敏结果的发展相关。研究人员从331名6月大的婴幼儿中分离了PBMCs细胞,之后在体外利用流感嗜血杆菌、卡他拉氏杆菌和肺炎链球菌对PBMCs细胞进行刺激。之后,利用电化学荧光免疫反应对各种细胞因子(IL-2, I